We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more



Completing Recruitment in Three Countries in a Phase 2b Study Despite Hurdles Caused by the Pandemic

A Sweden-based pharmaceutical company Staybe Therapeutics partnered with OCT Clinical, a leading CRO in Eastern Europe, to run a Phase 2b study in three European countries. 

This is a multicenter, randomized Phase 2b study, the primary goal of which is to evaluate the efficacy of the study medicine vs. placebo. The study is double-blinded, which means that neither the patient nor the treating physicial nows whether the patient is receiving a high or low dose of STA363 - the medince under study - or a placebo. All trial participants are followed-up for 12 months. 

Download the full text of this case study to learn more about the project. 

Thank you for your request!
Our team will respond to you within 24 hours.